MARKET

MLLCF

MLLCF

Molecular Partnr
OTCPK
2.550
NaN%
Closed 09:30 06/09 EDT
OPEN
--
PREV CLOSE
2.550
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
4.100
52 WEEK LOW
2.320
MARKET CAP
95.65M
P/E (TTM)
-2.0114
1D
5D
1M
3M
1Y
5Y
1D
Molecular Partners to hold trial-in-progress presentations on Phase 1/2a study
TipRanks · 05/31 20:30
Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
TipRanks · 05/12 23:15
Molecular Partners publishes MP0317 clinical data in Nature Cancer
TipRanks · 05/01 11:32
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
TipRanks · 04/22 10:25
Molecular Partners announces presentation of preclinical data at AACR
TipRanks · 04/19 16:55
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
TipRanks · 03/16 10:26
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
TipRanks · 03/16 05:45
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
TipRanks · 03/13 16:15
More
About MLLCF
Molecular Partners AG is a Switzerland-based company engaged in the pharmaceuticals industry. As a biopharmaceutical company, it is active in the research and development of proteins like DARPins (Designed Ankyrin Repeat Proteins), a new class of small proteins used for the development of medicine against diseases like cancer and sight-threating diseases, among others. The Company’s pipeline is structured mainly through three areas: Ophthalmology, including the creation of therapies for renital diseases like wet age-related macular degeration (wet AMD) and diabetic macular edema (DME); Oncology, containing the development of DARPins against cancer, among others; and Immunology and other Indications, entailing DARPins against several targets important for the treatment of inflammatory and auto-immune diseases.

Webull offers Molecular Partners AG stock information, including OTCPK: MLLCF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MLLCF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MLLCF stock methods without spending real money on the virtual paper trading platform.